Industry News

Pharmaceutical Industry News

As Novo Nordisk continues its epic…

September 14th, 2026|Fierce Pharma|

As Novo Nordisk continues its epic battle with Eli Lilly for market share in the increasingly competitive obesity and diabetes space, Novo is launching a major rebranding of its business, its logo and its name.

Healthcare marketing and comms…

September 13th, 2026|Fierce Pharma|

Healthcare marketing and comms agency, Deerfield Group, is creating a new model for growth while making a series of appointments and promotions to help bolster its plans.

GSK is advancing its inaugural…

September 12th, 2026|Fierce Pharma|

GSK is advancing its inaugural lung cancer asset, Jideytro, toward a landmark first-line FDA approval, aided by an unprecedented complete response rate.

Etcamah now joins Roche’s rival…

September 12th, 2026|Fierce Pharma|

Etcamah now joins Roche’s rival oral SERD, giredestrant, in missing the mark in first-line HR+/HER2- breast cancer, spelling trouble for others’ efforts in the same setting.

Newly revealed global phase 3 data…

September 11th, 2026|Fierce Pharma|

Newly revealed global phase 3 data from Merck and Gilead’s failed Trodelvy first-line non-small cell lung cancer trial could reignite the question around translating Chinese data to the West.

A preliminary 15% higher death…

September 11th, 2026|Fierce Pharma|

A preliminary 15% higher death risk in a phase 3 trial threatens to thwart AstraZeneca and Daiichi Sankyo’s bid to establish their star ADC Enhertu as a first-line treatment for patients with HER2-mutant non-small cell

Takeda’s long-time R&D chief…

September 11th, 2026|Fierce Pharma|

Takeda's long-time R&D chief Andy Plump will retire. Daiichi Sankyo beat back a $1.3 billion damage claim in a lawsuit. Samsung Biologics signed a $262 million contract with an unnamed client. And more.

Argonaut Manufacturing Services, a…

September 11th, 2026|Fierce Pharma|

Argonaut Manufacturing Services, a CDMO specializing in aseptic fill-finish for injectable biologics and other drugs, has sold its life sciences and diagnostics unit to the private equity firm 1315 Capital for an undisclosed price.

In his first interview after…

September 10th, 2026|Fierce Pharma|

In his first interview after taking the reins of the FDA’s Oncology Center of Excellence, Angelo de Claro, M.D., is outlining a regulatory agenda that prioritizes organizational strength and continued regulatory modernization.

Lonza’s plans for a new…

September 10th, 2026|Fierce Pharma|

Lonza's plans for a new spray-drying facility in Bend, Oregon, affirm the company's commitment both to high-margin medicines and the U.S. At the same time, fellow Swiss CDMO CordenPharma is also making expansion moves, albeit

With positive phase 3 results in…

September 10th, 2026|Fierce Pharma|

With positive phase 3 results in hand, AbbVie is one step closer to expanding the reach of its key migraine preventative Qulipta, also known as atogepant.

In a move that at least one local…

September 10th, 2026|Fierce Pharma|

In a move that at least one local HIV charity has deemed “profoundly disappointing,” England's health technology assessor NICE is currently recommending against coverage of Gilead Sciences’ landmark twice-a-year PrEP medication lenacapavir on the National

As Samsung Biologics works to…

September 10th, 2026|Fierce Pharma|

As Samsung Biologics works to close a massive buyout to branch out into peptides, the Korean CDMO’s bread-and-butter contracting work continues to gin up big-ticket contracts from the drug industry.